Abstract: A method is provided for rehabilitating or restoring the vasorelaxant action of the endothelium impaired by atherosclerosis and/or hypercholesterolemia, thereby preventing arteriospasm in the coronary arteries using an angiotensin converting enzyme inhibitor such as captopril, fosinopril, ceranapril, enalapril or lisinopril, which may be administered by oral or parenteral dosage forms.
Abstract: This invention discloses that certain types of non-addictive opioid drugs such as dextromethorphan (which is widely used in cough syrups) provide a highly effective means of treating the feelings and symptoms of emotional lability in at least some patients suffering from neurologic impairment, without sedating, tranquilizing, or otherwise significantly interfering with consciousness or alertness in the patient. In several patients tested to date who were suffering from amyotrophic lateral sclerosis (ALS), dextromethorphan, administered orally, was remarkably effective and became quite obvious to the patients even though it was being tested for an entirely different purpose. Its effectiveness is enhanced by co-administration of a second drug such as quinidine which reduces the degradation of dextromethorphan by oxidative enzymes and which therefore increases dextromethorphan concentrations in the blood.
Abstract: A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals containing 1 to 4 carbon atoms, R.sub.2 and R.sub.3 are independently selected from the group consisting of H, oxo, and alkyl radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms.
Abstract: The compound of the formula ##STR1## in which, independently of one another, R.sup.1 and R.sup.4 are hydrogen or hydroxyl,R.sup.2 and R.sup.3 are hydroxyl,R.sup.5 is hydrogen, hydroxyl or an oxo group, andR.sup.2 and R.sup.3, and R.sup.3 and R.sup.4, can each together form a double bond,has hypolipemic properties and is used for the preparation of a pharmaceutical for lowering serum cholesterol.
Type:
Grant
Filed:
August 26, 1991
Date of Patent:
April 6, 1993
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Ernold Granzer, Peter Hammann, Joachim Wink, Susanne Grabley
Abstract: A method for inhibiting oxytocin activity by administering an oxytocin inhibiting amount of a penicillide compound having the formula ##STR1## and compositions for such use are described.
Abstract: The invention provides pharmaceutical compositions comprising hypolipidemically active derivatives of 1,2,4-triazolidine-3,5-diones, 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones, and 1,3,5-triazine-2,4(1H,3H)-diones in a pharmaceutically acceptable carrier for treating hyperlipidemia in mammals, particularly humans.
Type:
Grant
Filed:
November 6, 1990
Date of Patent:
March 9, 1993
Assignees:
North Carolina Central Univ., University of North at Chapel Hill
Abstract: Uridine is used to treat the peripheral complications of diabetes, such as neuropathy, retinopathy and vasculopathy, thanks to its characteristics of promotor of glycogen endocellular biosynthesis. 40 diabetic patients were treated for six months with uridine or with placebo in a double-blind clinical teat.
Type:
Grant
Filed:
May 22, 1991
Date of Patent:
March 2, 1993
Assignee:
Polifarma S.p.A.
Inventors:
Mario Materazzi, Vincenzo Politi, Giovanni Di Stazio, Giovanna De Luca
Abstract: Compounds of formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions associated with cerebral ischaemia, e.g. stroke.
Type:
Grant
Filed:
December 12, 1990
Date of Patent:
March 2, 1993
Assignee:
Sandoz Ltd.
Inventors:
Joachim Nozulak, Andre Sauter, Jean-Marie Vigouret
Abstract: The present invention relates to a method for providing a patient with neuroprotective effect, which consists in administering modafinil to said patient.
Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylatin. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
Abstract: The present invention provides sulphonamides of the general formula: ##STR1## wherein R is a hydrogen or halogen atom, a cyano group or a C.sub.1 -C.sub.6 -alkyl or trifluoromethyl radical, n is 1, 2 or 3, m is 0 or 1 to 5, X is a valency bond, an oxygen atom, a carbonyl group or a --CHOH-- group, A is a valency bond or a carbonyl group and B is a valency bond or an --NH-- group; the physiologically acceptable salts thereof with inorganic and organic acids, as well as the optical isomers thereof.The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.
Abstract: The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --;R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, orR is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; andthe dotted line represents an optional double bond;or of a physiologically acceptable salt or acid derivative thereof.Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Type:
Grant
Filed:
June 14, 1991
Date of Patent:
October 6, 1992
Assignee:
Burroughs Wellcome Co.
Inventors:
Anjaneyulu S. Tadepalli, Walker A. Long, James W. Crow, Kenneth B. Klein
Abstract: A germicidal composition is disclosed which comprises a solvent containing at least 50% by weight of a stabilizing liquid selected from 3-methyl-3-methoxybutyl alcohol and an isothiazolone compound dissolved in the solvent.
Abstract: A method of treating livestock infected with, or protecting livestock against infection from, bacteria which comprises administering to such livestock an antibacterially effective amount of a quinolonecarboxylic acid or derivative of the formula ##STR1## in which A represents nitrogen or .dbd.C--R.sup.4,R.sup.4 represents hydrogen, fluorine, chlorine, nitro or methyl,B represents ##STR2## and B also represents ##STR3## when R.sup.1 does not denote cyclopropyl, and R.sup.5 represents hydrogen, a branched or unbranched alkyl group which has 1 to 4 carbon atoms and which can optionally be substituted by a hydroxyl or methoxy group,R.sup.6 represents hydrogen, methyl or phenyl,R.sup.7 represents hydrogen or methyl,R.sup.8 represents amino, alkyl- or dialkylamino having 1 or 2 carbon atoms in the alkyl group, aminomethyl, alkyl- or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group,R.sup.
Type:
Grant
Filed:
January 2, 1991
Date of Patent:
September 8, 1992
Assignee:
Bayer Aktiengesellschaft
Inventors:
Karl G. Metzger, Hans-Joachim Zeiler, Martin Scheer, Herbert Voege, Klaus Grohe
Abstract: A pharmaceutical composition suitable for oral administration comprises micronized progesterone in an oil vehicle which is high in glycerides of polyunsaturated fatty acids. Micronized progesterone particles suspended in such an oil vehicle are absorbed more readily into the bloodstream and achieve high progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of premenstrual syndrome.
Type:
Grant
Filed:
October 27, 1989
Date of Patent:
August 18, 1992
Assignee:
Genesis Systems Corporation
Inventors:
Wayne S. Maxson, Joel T. Hargrove, Philip G. Meyers
Abstract: Compounds of structural formula (I): ##STR1## are squalene synthestase inhibitors useful in inhibiting the biosynthesis of cholesterol in the treatment of hypercholesterolemia and related disorders.
Type:
Grant
Filed:
May 17, 1991
Date of Patent:
August 4, 1992
Assignee:
Merck & Co., Inc.
Inventors:
Alfred W. Alberts, Gregory D. Berger, James D. Bergstrom
Abstract: This invention relates to alkylamino alkylene derivatives of certain 2H-1-benzopyrans useful as plasma cholesterol lowering agents and to their end-use application as therapeutic agents.
Abstract: A process for lowering the blood cholesterol of hyperlipidemic patients by oral ingestion of pyruvate and a confection (cereal bar, fruit bar, candy) containing pyruvate as the ingestion medium.
Type:
Grant
Filed:
December 24, 1990
Date of Patent:
July 28, 1992
Assignee:
The Montefiore Hospital Association of Western Pennsylvania
Abstract: Pig mange mite infestations are controlled or eradicated by application of a pour-on formulation containing phosmet. A suitable regime is to apply about 20 mg/kg of phosmet to sows shortly before farrowing and to boars at six monthly intervals.
Abstract: The invention relates to new gem-diphosphonates derivatives substituted by phenol groups of formula (I): ##STR1## as well as the process for their preparation and the pharmaceutical compositions containing them.
Type:
Grant
Filed:
July 31, 1991
Date of Patent:
July 7, 1992
Assignee:
Symphar S.A.
Inventors:
Lan Nguyen, Eric Niesor, Hieu Phan, Pierre Maechler, Craig Bentzen